The organic CER growth at -11% is a major negative surprise, and the H1 organic CER growth is 1%.
Redeye comments on Alligator Bioscience's second quarter report 2025.
We estimate Q2 2025 pre-tax profit of DKK 69m, down DKK 36m (34%) y/y.
- Q2 sales 8% below our ests. at SEK 202m, for -9% org.
- Q2: Sales 6% above, EBITDA NOK 7m vs ABGSCe NOK 3m - Positive development in projects - Only minor...
Redeye comments on Lime’s Q2 report, showing solid underlying numbers despite sales being hurt by so...
Redeye updates its production estimates ahead of Arise's Q2 report on Friday next week (18 July).
Incap has guided for net sales to grow by 0-20% for 2025.
- We cut '25e-'27e adj. EBITA by 5-4% - Pressure on demand and hourly prices - NTM EV/EBITA below 7x...
- Earnings naturally hedged - Potential to generate order intake above the historical average - NTM ...
- '25e-'27e adj. EBITA down 5-3% - Weaker UK retail sales could impede EBITA growth - '25e EV/adj.
- Occupancy improvement in Q2 - Management open for more accretion - 2025e P/CEPS at 14x, ~12.
Prisma Properties, noterat i juni 2024, fokuserar på externa handelsplatser i trafiknära lägen med i...
Redeye is growing more optimistic about the investment case in Oncopeptides after two news items thi...
Finnair reports Q2 results on Jul 16. Industrial action has continued to affect performance, while t...
Redeye provides an initial take on Waystream’s Q2 numbers that were presented this morning, which ca...
Redeye comments on Carasent’s Q2 report, showing a more positive outlook than the preliminary figure...
Redeye comments on Invisio ahead of Q2-results (due 18 July) where we expect sequential improvement ...
Redeye lifts its ARR and EBITDA-CAPEX estimates for Litium after the Q2 report, where ARR growth sig...
Redeye publishes a preview of Transtema’s Q2 report.
